Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

Autor: Bibian M. E. Tullemans, Sanne L. N. Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W. P. J. van den Berkmortel, Natascha A. J. B. Peters, Peter de Bruijn, Stijn L. W. Koolen, Johan W. M. Heemskerk, Maureen J. B. Aarts, Marijke J. E. Kuijpers

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)

Abstract Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the T

Externí odkaz: https://doaj.org/article/bac1127f83e544248d1468261a8425b1

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients

Autor: Bibian M. E. Tullemans, Magdolna Nagy, Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G. A. oude Egbrink, Maureen Aarts, Johan W. M. Heemskerk, Marijke J. E. Kuijpers

Publikováno v: Frontiers in Cardiovascular Medicine, Vol 5 (2018)

Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of prot

Externí odkaz: https://doaj.org/article/05bd1e87d2794475abf3d48437cee59b

Effects of Cancer Presence and Therapy on the Platelet Proteome

Autor: Henk J. Broxterman, Henk L. Dekker, Henk M.W. Verheul, Mirjam G.A. oude Egbrink, Connie R. Jimenez, Jaco C. Knol, Thang V. Pham, Maudy Walraven, Siamack Sabrkhany, Sander R. Piersma, Inge de Reus, Arjan W. Griffioen

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, 22
International Journal of Molecular Sciences, 22(15):8236. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences, Vol 22, Iss 8236, p 8236 (2021)
International Journal of Molecular Sciences; Volume 22; Issue 15; Pages: 8236
Walraven, M, Sabrkhany, S, Knol, J C, Dekker, H, de Reus, I, Piersma, S R, Pham, T V, Griffioen, A W, Broxterman, H J, Oude Egbrink, M, Verheul, H M W & Jimenez, C R 2021, ' Effects of Cancer Presence and Therapy on the Platelet Proteome ', International Journal of Molecular Sciences, vol. 22, no. 15, 8236 . https://doi.org/10.3390/ijms22158236
International journal of molecular sciences, 22(15):8236. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences, 22, 15

Contains fulltext : 238212.pdf (Publisher’s version ) (Open Access) Platelets are involved in tumor angiogenesis and cancer progression. Previous studies indicated that cancer could affect platelet content. In the current study, we investigated whe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb6dbcb1574f3512b03e398858f1a79
http://europepmc.org/articles/PMC8347210

Platelets:the holy grail in cancer blood biomarker research?

Autor: Arjan W. Griffioen, Marijke J.E. Kuijpers, Siamack Sabrkhany, Mirjam G.A. oude Egbrink

Publikováno v: Sabrkhany, S, Kuijpers, M J E, Griffioen, A W & Oude Egbrink, M G A 2019, ' Platelets : the holy grail in cancer blood biomarker research? ', Angiogenesis, vol. 22, no. 1 . https://doi.org/10.1007/s10456-018-9651-4
Angiogenesis, 22(1), 1-2. Springer, Cham
Angiogenesis, 22(1). Springer Netherlands

We would like to promote the fact that platelets are increasingly emerging as a rich source of potential biomarkers for cancer. Blood platelets contain vast amounts of bioactive proteins, such as growth factors, chemokines, and cytokines. These prote

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4493e7d46f81ace63efa1ef78cea8d
https://research.vumc.nl/en/publications/1f5f8095-36f5-4525-acd3-1913a830c763

Role of the tumor stroma in resistance to anti-angiogenic therapy

Autor: Elisabeth J. M. Huijbers, Judy R. van Beijnum, Patrycja Nowak-Sliwinska, Siamack Sabrkhany, Victor L. Thijssen, Arjan W. Griffioen

Publikováno v: Drug Resistance Updates, 25, 26-37. Churchill Livingstone
Huijbers, E J M, van Beijnum, J R, Thijssen, V L, Sabrkhany, S, Nowak-Sliwinska, P & Griffioen, A W 2016, ' Role of the tumor stroma in resistance to anti-angiogenic therapy ', Drug Resistance Updates, vol. 25, pp. 26-37 . https://doi.org/10.1016/j.drup.2016.02.002

Several angiogenesis inhibitors are currently used in the clinic for treatment of cancer. While anti-angiogenesis treatment can improve treatment outcome, the overall benefit on patient survival is still rather limited. This is partially explained by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406626da5c106c47067fc185ab045908
https://doi.org/10.1016/j.drup.2016.02.002